HUMIRA (adalimumab) is the first and only at-home treatment in its category for moderate to severe ulcerative colitis
HUMIRA treatment can be taken at home

HUMIRA is the first and only treatment in its category that is FDA approved for pediatric UC and that can be administered at home after proper training by a health care professional.

A majority of patients achieved remission

In a clinical study among pediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis, a majority of patients on HUMIRA achieved remission after just 8 weeks.
Many patients who responded by week 8 were in remission at 1 year. Individual results may vary.

Download the IBD Brochure

You’ll find useful information about pediatric inflammatory bowel diseases (IBD), including ulcerative colitis, and how treatment with HUMIRA may help. Bring the brochure with you to discuss with the doctor at your child’s next appointment.